BioSpace News Archive

Tygrus LLC announced that tests conducted by a Center for Disease Control and Prevention authorized Bio Safety Level 3 laboratory on its new ingredient, Tydracide, showed that the formulation eliminated the SARS-CoV-2 virus in 1 minute at greater than 5-Log reduction.

Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that Ronald Renaud, chief executive officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020, at 1:00 p.m. ET. A live webcast of the session will be accessib

The online learning program combines lab simulations and mentoring experiences focused on biotechnology and neurological diseases, such as Parkinson’s disease, Alzheimer’s disease and multiple sclerosis Four hundred students from Massachusetts and North Carolina are enrolling in this no-fee program that also provides students with computers and other technology resources The initiative builds upon Biogen’s Community Lab, which has enrolled more than 55,000 students to date, and the Lemelso

Invitae Corporation, a leading medical genetics company, announced that members of its management team will virtually present at the William Blair 40th Annual Growth Stock Conference on Thursday, June 11, 2020 at 9:20 a.m. Central / 7:20 a.m. Pacific.

Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced the appointment of Susan A. Knudson as Executive Vice President and Chief Financial Officer.

AB201 (rNAPc2) is being developed as a potential treatment for COVID Associated Coagulopathy , a condition characterized by abnormal blood clotting in patients with COVID-19 Previous safety data in more than 700 patients through Phase 2 may enable more rapid development ARCA anticipates filing an IND in the third quarter of 2020 and initiating late-stage clinical testing in the second half of this year Prior rNAPc2 results treating Ebola and Marburg viral infections in non-huma

Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”) today announces that the Company management will present at the Jefferies Virtual Healthcare Conference. Jefferies Virtual Healthcare Conference Date: June 2 – June 4, 2020 Company Presentation: Thursday, June 4, 2020 at 4:00 pm (ET) Presenter: Jeffrey A. Meckler ,

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley , president and chief executive officer, will be participating in the following investor conferences: Jefferies Virtual Healthcare Conference at 10:00 a.m. ET / 7:00 a.m. PT on Thursday , June 4, 2020 Goldman Sachs 41 st Annual Healthcare Conference a

Lead pipeline investigational compound, SM-88, represents a new approach designed to selectively disrupt cancers metabolic process leading to cancer cell death SM-88 has demonstrated clinical responses in 15 different cancer types across four separate studies TYME-88-Panc pivotal trial enrolling patients using oral SM-88 as a potential treatment for third-line pancreatic cancer PanCAN enrolling patients in its Precision Promise SM adapt

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present a corporate overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 3 at 10:30 a.m. ET. A live audio webcast of the presentation will be available under the “Investors and Media” section of Seres’ website. A replay of the presentation will become available approximately one hour after the event and will be archived for